Patent 11957791 was granted and assigned to Intra-Cellular Therapies on April, 2024 by the United States Patent and Trademark Office.
The present disclosure relates to solid oral dosage forms comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.